[1]李娟,翁洁琼,卢雯平.益气活血解毒方治疗晚期上皮性卵巢癌疗效相关靶基因筛选[J].中国中医药信息杂志,2020,27(4):28-34.[doi:10.3969/j.issn.1005-5304.201910465]
 LI Juan,WENG Jieqiong,LU Wenping.Screening of Target Genes Related to Efficacy of Yiqi Huoxue Jiedu Decoction for Advanced Epithelial Ovarian Cancer[J].zhongguo zhongyiyao xinxi zazhi,2020,27(4):28-34.[doi:10.3969/j.issn.1005-5304.201910465]
点击复制

益气活血解毒方治疗晚期上皮性卵巢癌疗效相关靶基因筛选

参考文献/References:

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin,2019,69(1):7-34.

[2] LHEUREUX S, BRAUNSTEIN M, OZA A M. Epithelial ovarian cancer:Evolution of management in the era of precision medicine[J]. CA Cancer J Clin,2019,69(4):280-304.

[3] LU H, ARSHAD M, THORNTON A, et al. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer[J]. Nat Commun,2019,10(1):764.

[4] 中国抗癌协会妇科肿瘤专业委员会.中国卵巢上皮性癌维持治疗专家共识(2019)[J].中国实用妇科与产科杂志,2019,35(6):655-659.

[5] 卢雯平,马丹,闫会苓,等.晚期卵巢癌常规治疗后中医维持治疗的疗效分析[J].国际中医中药杂志,2014,36(1):13-16.

[6] 夏恺,闫荟苓,卢雯平.益气活血解毒方对晚期卵巢癌患者无复发生存时间及生活质量的影响[J].中国医药,2014,9(2):244-246.

[7] 中华人民共和国卫生部医政司.中国常见恶性肿瘤诊治规范[M].2版.北京:北京医科大学中国协和医科大学联合出版社,1996:16.

[8] MUTCH D G, PRAT J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer[J]. Gynecol Oncol,2014,133(3):401-404.

[9] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:216-224.

[10] ASHBURNER M, BALL C A, BLAKE J A, et al. Gene ontology:tool for the unification of biology. The Gene Ontology Consortium[J]. Nat Genet,2000,25:25-29.

[11] KANEHISA M, GOTO S, KAWASHIMA S, et al. The KEGG resource for deciphering the genome[J]. Nucleic Acids Res,2004,32(Database issue):D277-280.

[12] YI M, HORTON J D, COHEN J C, et al. WholePathwayScope:a comprehensive pathway-based analysis tool for high-throughput data[J]. BMC Bioinformatics,2006,7:30.

[13] LI C, LI H. Network-constrained regularization and variable selection for analysis of genomic data[J]. Bioinformatics,2008, 24(21):1175-1182.

[14] 秦静波,王济,孟翔鹤,等.表观遗传学与体质可调论关系的探析[J].辽宁中医杂志,2018,45(4):727-729.

[15] 张振华,李娟,卢雯平.益气活血解毒方治疗晚期卵巢癌有效可能的单核苷酸多态性位点及基因靶点[J].中国医药,2018,13(4):601-605.

[16] 夏恺,车焕丽,卢雯平.晚期卵巢癌中医证型分布规律研究[J].新中医,2013,45(4):109-112.

[17] YALNIZ F F, DAVER N, REZVANI K, et al. A pilot trial of lirilumab with or without azacitidine for patients with myelodysplastic syndrome[J]. Clin Lymphoma Myeloma Leuk,2018,18(10):658-663,e2.

[18] BELLEMARE-PELLETIER A, TREMBLAY J, BEAULIEU S, et al. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC classⅡ antigen processing[J]. J Leukoc Biol,2005,78(1):95-105.

[19] KORNILUK A, KEMONA H, DYMICKA-PIEKARSKA V. Multifunctional CD40L:pro- and anti-neoplastic activity[J]. Tumour Biol,2014, 35(10):9447-9457.

[20] OUSSA N A, DAHMANI A, GOMIS M, et al. VEGF requires the receptor nrp-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation[J]. J Immunol,2016,197(10):3927-3935.

[21] MURUGAIYAN G, MARTIN S, SAHA B. CD40-induced countercurrent conduits for tumor escape or elimination?[J]. Trends Immunol, 2007,28(11):467-473.

[22] DUNNILL C J, IBRAHEEM K, MOHAMED A, et al. A redox state- dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis[J]. Oncogene,2017,36(18)2515-2528.

[23] LEVIN N, PATO A, CAFRI G, et al. Spontaneous activation of antigenpresenting cells by genes encoding truncated homo-oligomerizing derivatives of CD40[J]. J Immunother,2017, 40(2):39-50.

[24] QU Q X, HUANG Q, XU J, et al. CD40 signal regulates CXCR4 mediating ovarian carcinoma cell migration:implications for extrapelvic metastastic factors[J]. Oncol Res,2013,20(9):383- 392.

[25] LIU C, PENG W, XU C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice[J]. Clin Cancer Res,2013,19(2):393-403.

[26] ATSAVES V, LEVENTAKI V, RASSIDAKIS G Z, et al. AP-1 transcription factors as regulators of immune responses in cancer[J]. Cancers (Basel),2019,11(7):1037-1058.

[27] TAWBI HA H, AMARIA R N, GLITZA I C, et al. Safety and preliminary activity data from a single center phase Ⅱ study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM)[J]. J Clin Oncol,2018,36(15_suppl):9560.

[28] DUMMER R, FERNÁNDEZ A M A, HANSSON J, et al. Preliminary findings from part 1 of COMBI-i:A phase Ⅲ study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma[J]. J Clin Oncol,2018,36(5_suppl):189.

[29] DE LUCA A, MAIELLO M R, D’ALESSIO A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways:role in cancer pathogenesis and implications for therapeutic approaches[J]. Expert Opin Ther Targets,2012,16(Suppl 2):S17-27.

[30] CHEN K, LIU M X, MAK C S, et al. Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways[J]. Theranostics,2018, 8(2):423-436.

[31] GYÖRFFY B, LANCZKY A, EKLUND A C, et al. An online survival analysis tool to rapidly assess the effect of 22277 genes on breast cancer prognosis using microarray data of 1809 patients[J]. Breast Cancer Res Treat,2010,123(3):725-731.

备注/Memo

基金项目:国家自然科学基金面上项目(81774104、8197532);国家自然科学基金青年基金(81403240)(收稿日期:2019-10-16)(修回日期:2019-11-11;编辑:华强)

更新日期/Last Update:

2020-03-20